Plain-English translation of NCT06138132 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing KYV-101, a new type of treatment that uses your own immune cells to fight multiple sclerosis. Specifically, the treatment removes certain immune cells from your blood, trains them in the laboratory to target and destroy B cells (immune cells that contribute to MS), and then infuses them back into your body. This approach is being studied in patients with progressive forms of MS that have stopped responding to available treatments.
Most current MS treatments work best for relapsing forms of the disease, but there are very few effective options for progressive MS—especially when the disease is no longer showing signs of inflammation and is resistant to other medications. This trial exists to see whether this new treatment might help patients whose disease continues to worsen despite available therapies.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first undergo screening visits to confirm you have the right type of MS and that your health is suitable for the treatment. Then, your doctors will collect some of your blood cells through a procedure called apheresis (similar to donating blood plasma). These cells will be sent to a laboratory where they are trained to recognize and destroy specific immune cells linked to MS. After preparation, the cells will be infused back into your body during a hospital visit. You will then be monitored closely for safety and effectiveness over 12 months, with regular clinic visits and tests.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States